SHC:NSD-Sotera Health Co (USD)

COMMON STOCK | Diagnostics & Research |

Last Closing

USD 11.4

Change

+0.08 (+0.71)%

Market Cap

USD 3.10B

Volume

0.74M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-04-26 )

Largest Industry Peers for Diagnostics & Research

Symbol Name Price(Change) Market Cap
IDXX IDEXX Laboratories Inc

+6.81 (+1.43%)

USD 41.47B
ICLR ICON PLC

-0.60 (-0.19%)

USD 25.49B
ILMN Illumina Inc

-6.16 (-5.18%)

USD 19.47B
MEDP Medpace Holdings Inc

+1.36 (+0.34%)

USD 12.27B
NTRA Natera Inc

-0.06 (-0.06%)

USD 11.20B
EXAS EXACT Sciences Corporation

-1.94 (-3.06%)

USD 10.68B
RDNT RadNet Inc

+0.47 (+0.90%)

USD 3.57B
OLK Olink Holding AB ADR

+0.07 (+0.30%)

USD 2.72B
NEOG Neogen Corporation

+0.27 (+2.22%)

USD 2.63B
GH Guardant Health Inc

-0.28 (-1.47%)

USD 1.96B

ETFs Containing SHC

IUKP:SW iShares UK Property UCITS.. 3.54 % 0.00 %

+0.09 (+-0.14%)

USD 0.63B
UKPH:XETRA iShares UK Property UCITS.. 3.33 % 0.00 %

+0.05 (+-0.14%)

USD 0.64B
LSEQ Harbor Long-Short Equity .. 2.67 % 0.00 %

-0.04 (-0.14%)

USD 0.01B

Market Performance

  Market Performance vs. Industry/Classification (Diagnostics & Research) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -32.34% 32% F 17% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -32.34% 32% F 17% F
Trailing 12 Months  
Capital Gain -32.02% 49% F 27% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -32.02% 49% F 27% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -7.22% 46% F 30% F
Dividend Return -7.22% 46% F 29% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 37.45% 73% C 48% F
Risk Adjusted Return -19.27% 45% F 31% F
Market Capitalization 3.10B 85% B 85% B

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector